Literature DB >> 29117608

[Assessment of Cyclofusion Capabilities of Normal Subjects with 3D Dynamic Random-Dot Stereograms].

Jan Heckmann1, Veit Sturm1, Klara Landau2, Béla Török1.   

Abstract

BACKGROUND: Evaluation of a new method for cyclofusion measurement. PATIENTS AND METHODS: The maximal incyclofusion and excyclofusion tolerated of 20 normal subjects (15 females, mean age 36 ± 9.9 years) were measured by computer-generated dynamic random-dot stereograms (DRDS). Subjects had to detect the orientation of only binocularly visible Landolt C stimuli randomly presented with a 3-D monitor. Both eyes were separately stimulated with shutter glasses. The DRDS-pattern projected to the left and right eye were rotated in the opposite direction in 0.5° steps. In 10 subjects, cyclofusion measurements were repeated.
RESULTS: Incylofusional amplitudes were between 2.5° and 6°, excyclofusional amplitudes measured between 3° and 5.5°. Mean incyclofusion was 3.71° (SD 0.82) and mean excyclofusion measured 4.24° (SD 0.73). Repeated measurements of incyclofusion and excyclofusion in the same subject demonstrated a difference of about 0.5° (0.55° for incyclofusion, 0.45° for excyclofusion).
CONCLUSIONS: The DRDS Landolt C method provided a reliable assessment with good reproducibility of cyclofusion in healthy subjects with only binocularly perceivable objects. Our cyclofusional capabilities were slightly higher than those received with dissociating 2D measurements. Georg Thieme Verlag KG Stuttgart · New York.

Entities:  

Mesh:

Year:  2017        PMID: 29117608     DOI: 10.1055/s-0043-118100

Source DB:  PubMed          Journal:  Klin Monbl Augenheilkd        ISSN: 0023-2165            Impact factor:   0.700


  1 in total

1.  Comparison of torsional amplitudes between emmetropes and myopes using after-image slides.

Authors:  Antony Arokiadass Baskaran; Tanuja Britto; Sundaresan Rajkumar; Philip A Thomas; C A Nelson Jesudasan
Journal:  Indian J Ophthalmol       Date:  2019-05       Impact factor: 1.848

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.